USA - engelsk - NLM (National Library of Medicine)

oceanside pharmaceuticals - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium sulfate (unii: 0ypr65r21j) (sodium sulfate anhydrous - unii:36kcs0r750), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - polyethylene glycol-3350, electrolytes, and ascorbate for oral solution is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults. polyethylene glycol-3350, electrolytes, and ascorbate for oral solution is contraindicated in the following conditions: risk summary there are no available data on polyethylene glycol-3350, electrolytes, and ascorbate for oral solution in pregnant women to inform a drug-associated risk for adverse developmental outcomes. animal reproduction studies have not been conducted with polyethylene glycol-3350, electrolytes, and ascorbate for oral solution. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary the

USA - engelsk - NLM (National Library of Medicine)

westminster pharmaceuticals, llc - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl), sodium citrate, unspecified form (unii: 1q73q2julr) (anhydrous citric acid - unii:xf417d3psl), citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate, sodium citrate and citric acid oral solution is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract. in addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. it is also effective in correcting the acidosis of certain renal tubular disorders. this product is highly concentrated and when administered after meals and before bedtime, allows one to maintain an alkaline urine ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in recommended dosages. it is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. potassium citrate and sodium citrate do not neutralize the gastric juice or disturb digestion. severe renal impairment with ol

Israel - engelsk - Ministry of Health

teva medical marketing ltd. - sodium chloride - solution for infusion - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

Israel - engelsk - Ministry of Health

teva medical marketing ltd. - sodium chloride - solution for infusion - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

Irland - engelsk - HPRA (Health Products Regulatory Authority)

b. braun medical limited - sodium chloride; potassium chloride; sodium lactate solution; calcium chloride dihydrate - solution for infusion - per cent - solutions affecting the electrolyte balance; electrolytes

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

USA - engelsk - NLM (National Library of Medicine)

hospira, inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - sodium chloride 4.5 g in 1000 ml - potassium chloride in sodium chloride injection, usp is indicated as a source of water and electrolytes. none known. to open tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. to add medication - prepare additive port. prepare additive port. - using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. withdraw needle after injecting medication. using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. withdraw needle after injecting medication. - the additive port may be protected by covering with an a

USA - engelsk - NLM (National Library of Medicine)

hospira, inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - sodium chloride 234 mg in 1 ml - 23.4% sodium chloride injection, usp is indicated for use as an electrolyte replenisher in parenteral fluid therapy. it serves as an additive for total parenteral nutrition (tpn) and as an additive for carbohydrate containing i.v. fluids. 23.4% sodium chloride injection, usp additive solution is contraindicated in patients with hypernatremia or fluid retention.

USA - engelsk - NLM (National Library of Medicine)

kvk-tech, inc. - sodium sulfate (unii: 0ypr65r21j) (sodium sulfate anhydrous - unii:36kcs0r750), potassium sulfate (unii: 1k573lc5tv) (sulfate ion - unii:7is9n8kpmg), magnesium sulfate (unii: de08037sab) (magnesium cation - unii:t6v3lhy838) - sodium sulfate 17.5 g in 22.7 g - colprep kit is indicated for cleansing of the colon as a preparation for colonoscopy in adults. - gastrointestinal obstruction - bowel perforation - gastric retention - ileus - toxic colitis or toxic megacolon - known allergies to components of the kit [see description (11)] teratogenic effects: pregnancy category c. animal reproduction studies have not been conducted with colprep kit. it is also not known whether colprep kit can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. colprep kit should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when colprep kit is administered to a nursing woman. the safety and effectiveness of colprep kit have not been established in pediatric patients. of the 375 patients who received another oral formulation of sodium sulfate (17.5 g), potassium sulfate (3.13 g), and magnesium sulfate (1.6 g)